GLP-1 Research Peptides in Canada: A Laboratory Guide
Last reviewed: September 2026
GLP-1 peptides sit at an awkward intersection in Canada. The same three or four molecules are, at once, the active ingredients of some of the most prescribed drugs in the country, the subject of a large and fast-moving research literature, and a category of lyophilised research materials sold to laboratories. Most pages on the internet blur those three things together. This guide separates them: what the GLP-1 class is, where the line between an authorized drug and a research material actually falls in Canada, what tirzepatide, retatrutide and semaglutide are as research compounds, and how to evaluate a supplier of GLP-1 research peptides in Canada on documentation rather than marketing.
What are GLP-1 peptides?
Glucagon-like peptide-1 (GLP-1) is an endogenous incretin hormone — a short peptide of about thirty amino acids that specialised cells in the lining of the gut release after eating. It acts on the GLP-1 receptor, which is expressed in the pancreas, the brain, the stomach and several other tissues, and its signalling is one of the ways the body coordinates the response to a meal. Native GLP-1 is cleared from circulation within minutes, which is why so much of the research effort since the 1980s has gone into analogues that resist that clearance.
Much of the foundational science is Canadian. The work of Daniel Drucker and colleagues at the Lunenfeld-Tanenbaum Research Institute in Toronto is a large part of why GLP-1 biology is understood as well as it is, and it is a reasonable place to start if you want the primary literature rather than a vendor’s summary.
“GLP-1 peptides” as a category therefore covers three different things: the native hormone, the receptor-agonist analogues that have become authorized prescription drugs in Canada, and research-grade versions of those analogues supplied as lyophilised powder for laboratory work. Approved GLP-1 drugs exist and are available only by prescription from a licensed prescriber and pharmacy. This guide is about the third category — research materials — which are a different thing, supplied on a different legal basis, and never a route to the first two. For a broader primer on the molecule class, see what peptides are.
Approved drugs vs research materials: the line that matters in Canada
Health Canada authorizes specific GLP-1 drug products, each with a Drug Identification Number, a product monograph and a named manufacturer. As of September 2026 the Drug Product Database lists semaglutide products (Ozempic, Wegovy and Rybelsus) and tirzepatide products (Mounjaro and Zepbound) as marketed prescription drugs. Those products are authorized for the indications stated in their monographs, are dispensed only through a licensed pharmacy on prescription, and are the only form in which a Canadian can lawfully obtain these molecules for use.
A lyophilised research peptide is not one of those products. It carries no DIN, no authorization and no monograph. It is supplied strictly as a reagent for in-vitro and laboratory research, labelled “for research use only — not for human consumption,” and it is not an equivalent to, a substitute for, or a cheaper version of any authorized drug. That distinction is the line that matters, and a supplier that blurs it — by describing research material as an “alternative” to a brand-name drug, or by publishing instructions for people — is telling you something about its compliance posture.
The coverage you may have read. In April 2026 Health Canada issued a public advisory about unauthorised injectable peptide products sold online, and national outlets including the CBC reported on it. The advisory’s core concern is that unauthorised products have not been assessed for safety, efficacy or quality and may contain unknown ingredients or contaminants. We are not going to argue with that. The documented risk is material of unverified identity and purity, sold with health claims, to people intending to use it on themselves — and the honest answer from a research-materials supplier is not a rebuttal but documentation: a per-batch, third-party Certificate of Analysis, published where anyone can check it, with a batch number that matches the vial. Quantum’s are on the Certificate of Analysis hub and archived at permanent URLs on the lab results page. Verification does not turn a research reagent into an approved drug — nothing does — but it is the only part of the advisory’s concern that a supplier can actually control.
Tirzepatide as a research peptide
Tirzepatide is a synthetic 39-amino-acid peptide that acts as an agonist at two receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. It was engineered from the GIP sequence with modifications that confer GLP-1 receptor activity and a fatty-acid side chain that extends its half-life to roughly five days. In the research literature it is the reference compound for dual incretin-receptor agonism, and in-vitro work with it typically concerns receptor binding and selectivity, signalling bias at each receptor, and comparison against single-receptor agonists.
Tirzepatide is also the active ingredient of two Health-Canada-authorized prescription drugs, Mounjaro and Zepbound. Research-grade tirzepatide is not either of those products and is not supplied as a substitute for them.
Tirzepatide research materials in Canada
Research-grade tirzepatide is supplied as a lyophilised powder in a sealed vial. What to verify before ordering is the same as for any research peptide, and it matters more here because the molecule is the API of an approved drug: a per-batch Certificate of Analysis from a named independent laboratory, an HPLC purity figure with mass-spectrometry identity confirmation, a batch number printed on the vial that matches the published report, and consistent research-use-only labelling with no health claims. Quantum stocks tirzepatide as a research peptide (30 mg vial), with its batch COA on the product page and the compound background on the tirzepatide library page. A retatrutide + tirzepatide research blend is listed separately as RETA + TIRZ.
Retatrutide: the triple agonist
Retatrutide is a single-peptide agonist at three receptors — GLP-1, GIP and glucagon — which is why the literature calls it a triple agonist. As of September 2026 it remains an investigational compound in late-stage clinical trials run by its developer; it is not an authorized drug in Canada, the United States or the European Union, and no product containing it has a DIN. The full treatment of retatrutide as a research compound, including its batch COA, lives on the RETA product page; the library pages for the RETA + TIRZ 18 mg and 27 mg blends cover the combined format.
“GLP-3” is a nickname, not a class
You will see retatrutide called “GLP-3” on forums and in some vendor copy. There is no such hormone and no such receptor. The nickname is shorthand for “the one after GLP-1 and the dual agonist,” and it says nothing about the pharmacology. The accurate description is a GLP-1/GIP/glucagon receptor triple agonist, and searches for “GLP-3” resolve to retatrutide.
Tirzepatide vs retatrutide in the research literature
The two compounds are compared constantly, and most of the comparisons you will find online are about human outcomes, which this page does not discuss. The factual differences that matter to a researcher are structural and regulatory:
| Property | Tirzepatide | Retatrutide |
|---|---|---|
| Receptor profile | Dual agonist: GIP receptor + GLP-1 receptor | Triple agonist: GLP-1 receptor + GIP receptor + glucagon receptor |
| Structural basis | 39-amino-acid peptide derived from the GIP sequence, lipidated for extended half-life | Peptide engineered for balanced activity across three receptors, lipidated for extended half-life |
| Regulatory status in Canada (Sept 2026) | API of two authorized prescription drugs (Mounjaro, Zepbound) | Investigational; not authorized anywhere |
| Published human trials | Completed phase 3 programme; extensive published literature | Phase 2 published; phase 3 programme ongoing |
| Research-material format | Lyophilised vial | Lyophilised vial; also supplied blended with tirzepatide |
Which receptor profile is “better” is a clinical question that will be settled by the trial programme and the regulator, not by a research-peptide supplier. A longer, plain-language read on the two molecules is in retatrutide vs tirzepatide; this page deliberately stops at structure and status.
Semaglutide as a research compound
Semaglutide is a GLP-1 receptor agonist — a single-receptor compound, which makes it the natural contrast to the dual and triple agonists above. Structurally it is a modified analogue of native GLP-1 with a substitution that protects it from enzymatic cleavage and a fatty-acid side chain that extends its half-life to about a week. It is the active ingredient of three Health-Canada-authorized prescription drugs: Ozempic, Wegovy and Rybelsus.
Quantum does not stock semaglutide as a research peptide. We include it here because it is the reference GLP-1R-selective compound in the literature and because a guide to GLP-1 research peptides that skipped it would be incomplete, not because there is anything to buy. If you are looking for semaglutide as a research material from another supplier, apply exactly the verification checks described below — the molecule being the API of a widely prescribed drug makes documentation more important, not less.
How to evaluate a GLP-1 research peptide supplier in Canada
The GLP-1 class attracts more sellers, more marketing and more regulatory attention than any other research-peptide category, which makes the ordinary supplier checks more decisive here. Four of them do most of the work.
A per-batch Certificate of Analysis you can match to the vial. Not a generic certificate, not a representative sample: a report tied to the lot number printed on the vial you receive, with a test date and the name of the laboratory that produced it. Quantum’s batches are tested by Peptide Test Canada and each report is archived at a permanent URL on the lab results page.
Third-party testing that reports both purity and identity. HPLC gives the purity figure; mass spectrometry confirms the molecule is the one on the label. A supplier reporting only one of the two is reporting half the picture. How peptides are tested explains both, and how to read a peptide COA walks through the certificate field by field.
Batch traceability on the vial itself. A batch number, manufacturing date and expiry printed on the label are what connect the paperwork to the material. Without them the COA is a document about some other vial.
Research-use-only discipline, especially in this category. A GLP-1 supplier whose product pages read like a clinic’s — brand-name comparisons, outcome language, instructions for people — is operating outside the research-materials framework the Health Canada advisory is about. Consistent research-use-only labelling on the vial, the page and the invoice is the signal to look for. The legal framework itself is explained on are peptides legal in Canada?, and the general purchase-and-verification process on how to buy research peptides in Canada.
Quantum’s current GLP-1-class research materials — tirzepatide, retatrutide and the RETA + TIRZ blend — are in the shop, each with its batch COA on the product page; the wider compound reference is in the peptide guide.
Frequently asked questions
Is Ozempic considered a peptide?
Yes. Semaglutide, the active ingredient in Ozempic, is a peptide — a modified analogue of the GLP-1 hormone. That does not make research peptides drugs, and it does not make Ozempic a research peptide: the line between the two is regulatory authorization, not chemistry. Ozempic is a Health-Canada-authorized prescription drug with a DIN; a research-grade peptide has neither.
Is GLP-1 the same as Ozempic?
No. GLP-1 is a natural hormone the body produces after eating. Ozempic is one branded prescription drug whose active ingredient, semaglutide, is a long-acting analogue that mimics GLP-1 at its receptor. Research GLP-1 analogues sold as laboratory materials are neither the hormone nor the drug — they are reagents supplied for in-vitro work only.
What are examples of GLP-1 drugs?
In Canada, the authorized products in this class include semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound), each listed in Health Canada’s Drug Product Database with its own DIN and prescribed for the indications in its product monograph. Research peptides are not on that list and are not equivalents of anything on it.
How can I get GLP-1 naturally?
You already do. GLP-1 is an endogenous hormone secreted by cells in the intestinal lining in response to eating, as part of the body’s normal response to a meal, and cleared again within minutes. This page discusses research compounds that act on the GLP-1 receptor; it does not offer advice on diet or on influencing hormone levels, which is a conversation for a healthcare professional.
Is tirzepatide covered in Canada?
Coverage questions concern the authorized drugs, Mounjaro and Zepbound, and the answer depends on the province and the insurer — your prescriber or plan administrator is the right source. Quantum’s tirzepatide is a research material supplied to laboratories; it is not a drug, is never dispensed, and has no relationship to any drug plan.
Is tirzepatide or retatrutide legal to buy in Canada?
Tirzepatide is the active ingredient of authorized prescription drugs in Canada, and retatrutide is an investigational compound with no authorization anywhere; neither is available to the public as a drug outside a prescription or a clinical trial. Research-grade versions are supplied to laboratories as reagents, for research use only and not for human use, on that basis alone. How Canada treats research peptides generally is set out on are peptides legal in Canada?
What dose of tirzepatide or retatrutide should be used?
We do not publish dosing, titration, cycle or reconstitution-volume information for any GLP-1 research compound, and we will not answer dosing questions by email or chat. These are laboratory research materials, not for human use; dosing of the authorized drugs is set by the product monograph and a prescriber, and nothing we supply is one of those drugs.
All compounds referenced on this page are supplied for laboratory research use only and are not for human or veterinary use. Regulatory statements reflect Health Canada’s Drug Product Database and public advisory as of September 2026; consult the primary sources for the current position. Page last reviewed September 2026.